First Graphene Valuation
Is M11 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of M11 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for M11?
Other financial metrics that can be useful for relative valuation.
What is M11's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | AU$38.90m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 36.6x |
Enterprise Value/EBITDA | -9.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does M11's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x | ||
BNN BRAIN Biotech | 1.1x | 12.4% | €61.4m |
BIG1 Bio-Gate | 1.4x | 25.7% | €8.9m |
NTG Nabaltec | 0.6x | 4.5% | €125.0m |
2HRA H&R GmbH KGaA | 0.1x | 7.6% | €176.1m |
M11 First Graphene | 38.2x | n/a | €39.6m |
Price to Earnings Ratio vs Industry
How does M11's PE Ratio compare vs other companies in the European Chemicals Industry?
Price to Sales Ratio vs Fair Ratio
What is M11's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 37.6x |
Fair PS Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?